Merus touts bis­pe­cif­ic an­ti­body ef­fi­ca­cy da­ta with a lat­er da­ta cut-off in un­com­mon NRG1+ can­cers: #ES­MO23

MADRID — Merus un­veiled fur­ther ef­fi­ca­cy da­ta on Mon­day for its bis­pe­cif­ic an­ti­body zeno­cu­tuzum­ab, which fur­ther demon­strates “ro­bust and durable” re­sponse in pa­tients with NRG1+ non …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER